Results 51 to 60 of about 461,371 (240)

Total Number of Alterations in Liquid Biopsies Is an Independent Predictor of Survival in Patients With Advanced Cancers. [PDF]

open access: yes, 2020
PurposeStudies have demonstrated an association between quantity of circulating tumor DNA (ctDNA) and poorer survival. We investigated the relationship between percent ctDNA (%ctDNA), total number of ctDNA alterations, and overall survival (OS) in liquid
Goodman, Aaron   +4 more
core  

Impact of chronic exposure to bevacizumab on EpCAM-based detection of circulating tumor cells [PDF]

open access: yes, 2015
BACKGROUND: Circulating tumor cells (CTCs) are often undetected through the immunomagnetic epithelial cell adhesion molecule (EpCAM)-based CellSearch(®) System in breast and colorectal cancer (CRC) patients treated with bevacizumab (BEV), where low ...
GAZZANIGA, PAOLA   +7 more
core   +1 more source

Non-invasive Technology Advances in Cancer—A Review of the Advances in the Liquid Biopsy for Endometrial and Ovarian Cancers

open access: yesFrontiers in Digital Health, 2020
Improving cancer survival rates globally requires improvements in disease detection and monitoring, with the aim of improving early diagnosis and prediction of disease relapse. Traditional means of detecting and monitoring cancers rely largely on imaging
Mark R. Openshaw, Terri P. McVeigh
doaj   +1 more source

Circulating Tumor Cell and Cell-free Circulating Tumor DNA in Lung Cancer [PDF]

open access: yesChonnam Medical Journal, 2016
Circulating tumor cells (CTCs) are tumor cells that are separated from the primary site or metastatic lesion and disseminate in blood circulation. CTCs are considered to be part of the long process of cancer metastasis. As a 'liquid biopsy', CTC molecular examination and investigation of single cancer cells create an important opportunity for providing
S. Andarini   +6 more
openaire   +3 more sources

Opportunities and challenges of liquid biopsy in liver cancer

open access: yesClinical Surgical Oncology, 2023
Liver cancer is currently the third leading cause of cancer-related mortality worldwide. Due to late diagnosis and difficulty in monitoring, there is a pressing need for early detection and recurrence monitoring in patients with liver cancer.
Yu-Chen Zhong   +5 more
doaj   +1 more source

Detection of activating estrogen receptor gene (ESR1) mutations in single circulating tumor cells [PDF]

open access: yes, 2017
Purpose: Early detection is essential for treatment plans before onset of metastatic disease. Our purpose was to demonstrate feasibility to detect and monitor estrogen receptor 1 (ESR1) gene mutations at the single circulating tumor cell (CTC) level in ...
Austin, Laura   +9 more
core   +2 more sources

Niche inheritance: a cooperative pathway to enhance cancer cell fitness though ecosystem engineering [PDF]

open access: yes, 2014
Cancer cells can be described as an invasive species that is able to establish itself in a new environment. The concept of niche construction can be utilized to describe the process by which cancer cells terraform their environment, thereby engineering ...
Barar J   +13 more
core   +2 more sources

Label-free isolation of prostate circulating tumor cells using Vortex microfluidic technology. [PDF]

open access: yes, 2017
There has been increased interest in utilizing non-invasive "liquid biopsies" to identify biomarkers for cancer prognosis and monitoring, and to isolate genetic material that can predict response to targeted therapies. Circulating tumor cells (CTCs) have
Che, James   +12 more
core   +1 more source

Comprehensive liquid biopsy analysis for monitoring NSCLC patients under second-line osimertinib treatment

open access: yesFrontiers in Oncology
BackgroundThe heterogeneous and complex genetic landscape of NSCLC impacts the clinical outcomes of patients who will eventually develop resistance to osimertinib.
Aliki Ntzifa   +5 more
doaj   +1 more source

Human plasmacytoid dendritic cells and cutaneous melanoma [PDF]

open access: yes, 2020
The prognosis of metastatic melanoma (MM) patients has remained poor for a long time. However, the recent introduction of effective target therapies (BRAF and MEK inhibitors for BRAFV600-mutated MM) and immunotherapies (anti-CTLA-4 and anti-PD-1) has ...
Bugatti, Mattia   +4 more
core   +2 more sources

Home - About - Disclaimer - Privacy